Next Article in Journal
ACTH and Polymorphisms at Steroidogenic Loci as Determinants of Aldosterone Secretion and Blood Pressure
Next Article in Special Issue
Stability Profiles and Therapeutic Effect of Cu/Zn Superoxide Dismutase Chemically Coupled to O-Quaternary Chitosan Derivatives against Dextran Sodium Sulfate-Induced Colitis
Previous Article in Journal
Trauma and Stem Cells: Biology and Potential Therapeutic Implications
Previous Article in Special Issue
Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2017, 18(3), 575;

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment

Department of Gastroenterology, Sachs’ Children and Youth Hospital, SE-11883 Stockholm, Sweden
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institute, SE-11883 Stockholm, Sweden
Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, SE-17776 Stockholm, Sweden
Department of Medicine Solna, Karolinska Institute, SE-17776 Stockholm, Sweden
Department of Women’s and Children’s Health, Karolinska Institute, SE-11776 Stockholm, Sweden
Center for Clinical Research and Department of Pediatrics, Västmanland Hospital Vasteras, SE-72189 Västerås, Sweden
Department of Gastroenterology, Danderyds Hospital, SE-18288 Stockholm, Sweden
Author to whom correspondence should be addressed.
Academic Editors: Laurent Peyrin-Biroulet and Silvio Danese
Received: 27 October 2016 / Revised: 22 February 2017 / Accepted: 27 February 2017 / Published: 7 March 2017
Full-Text   |   PDF [1079 KB, uploaded 7 March 2017]   |  


The role of trough serum infliximab (s-IFX) and antibodies toward IFX (ATI) during maintenance treatment remains unclear in children. The aim of the present study was to investigate trough s-IFX and ATI to identify any correlation with inflammatory activity and clinical response in a pediatric inflammatory bowel disease (IBD) cohort. We investigated the s-IFX trough levels in pediatric IBD patients (n = 45) on maintenance IFX treatment. Ninety-three blood samples were collected and demographics, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and albumin were recorded. The mean s-IFX trough level was 5.2 µg/mL. The mean trough s-IFX level was significantly higher in the samples taken during remission (7.2 µg/mL) compared to active disease (4.5 µg/mL, p < 0.05). The trough s-IFX levels correlated with ESR, CRP, and albumin. S-IFX was undetectable in eight of the patients, all with positive ATI and active disease. Surprisingly, clinical and biochemical remission was observed at only 26 of the 93 visits. The correlation between dose variations and changes in trough s-IFX was not evident. In line with studies in adults, the s-IFX trough levels correlated with response to infliximab. View Full-Text
Keywords: inflammatory bowel disease; Crohn’s disease; ulcerative colitis; trough levels; antibodies toward infliximab inflammatory bowel disease; Crohn’s disease; ulcerative colitis; trough levels; antibodies toward infliximab

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Rolandsdotter, H.; Marits, P.; Sundin, U.; Wikström, A.-C.; Fagerberg, U.L.; Finkel, Y.; Eberhardson, M. Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment. Int. J. Mol. Sci. 2017, 18, 575.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top